Ecolab, a manufacturer of resins used to make pharmaceuticals, recently announced it is constructing a biologics resin manufacturing facility in Landenberg for its King of Prussia-based Purolite business.
Purolite manufactures specialty purification resins for pharmaceutical, industrial, nutraceutical, and water applications. The facility will be the company’s first U.S. operations of its Global Biologics Division.
Ecolab will invest a minimum of $190 million into the project which is expected to create at least 170 new jobs over the next five years.
The facility will manufacture health care and life science products for the pharmaceutical, nutraceutical, and medical device, industries. It will include production facilities, cleanrooms, laboratories and office space.
The facility will allow Purolite to support the development and production of lifesaving clinical and commercial-scale therapeutics and will reduce the time needed to bring therapeutics to market, optimize productivity and increase yield.
Construction is underway with phase one expected to be completed by the first half of 2025.
The Landenberg facility will be Purolite’s sixth manufacturing facility globally and fourth location in Pennsylvania.
The Department of Community and Economic Development submitted a funding proposal for a $1,037,000 Pennsylvania First grant and encouraged Purolite to apply for the Qualified Manufacturing Innovation and Reinvestment Deduction program.